Overview
This year’s Master Protocol Workshop focuses on Adaptive Platform Trials (APTs), powerful trials that study multiple therapies with multiple patient populations at once. Join industry, patient, regulatory agency, and other government experts to explore funding and start-up considerations, regulatory engagement, and key operational concerns through the lens of four different APT implementation models. A panel of global regulators will share their perspectives on the implementation of these trials in their regions, application to a wide range of therapeutic areas beyond oncology, and progress toward global regulatory alignment.
Need approval in order to attend?
Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.Check out our 2019 Program!
Program Committee
-
Daniel Millar, MBA Senior Director, Strategic Business Transformation
Johnson & Johnson, United States -
Zoran Antonijevic, MSc Vice President, Statistical Consulting
Abond CRO Inc., United States -
Scott Berry, PhD President and Senior Statistical Scientist
Berry Consultants LLC, United States -
Abby Bronson, MBA Vice President, Patient Advocacy and External Innovation
Edgewise Therapeutics, United States -
Lisa LaVange, PhD Professor Emerita
University of North Carolina at Chapel Hill, United States -
Victoria Manax Rutson, MD Chief Medical Officer
Pancreatic Cancer Action Network, United States -
MaryAnn Morgan-Cox, PhD Senior Director, Immunology Design Hub
Eli Lilly and Company, United States -
Rui (Sammi) Tang Vice President, Global Head of Biometrics
Servier Pharmaceuticals, United States
Have an account?